• This record comes from PubMed

Polymer nanomedicines with enzymatically triggered activation: A comparative study of in vitro and in vivo anti-cancer efficacy related to the spacer structure

. 2022 Nov ; 46 () : 102597. [epub] 20220905

Language English Country United States Media print-electronic

Document type Journal Article, Research Support, Non-U.S. Gov't

Links

PubMed 36064033
DOI 10.1016/j.nano.2022.102597
PII: S1549-9634(22)00083-1
Knihovny.cz E-resources

Polymer nanomedicines with anti-tumor activity should exhibit sufficient stability during systemic circulation to the target tissue; however, they should release the active drug selectively in the tumor. Thus, choice of a tumor-specific stimuli-sensitive spacer between the drug and the carrier is critical. Here, a series of polymer conjugates of anti-cancer drugs doxorubicin and pirarubicin covalently bound to copolymers based on N-(2-hydroxypropyl)methacrylamide via various enzymatically cleavable oligopeptide spacers were prepared and characterized. The highest rate of the drug release from the polymer carriers in presence of the lysosomal protease cathepsin B was determined for the copolymers with Val-Cit-Aba spacer. Copolymers containing pirarubicin were more cytotoxic and showed higher internalization rate than the corresponding doxorubicin counterparts. The conjugates containing GFLG and Val-Cit-Aba spacers exhibited the highest anti-tumor efficacy in vivo against murine sarcoma S-180, the highest rate of the enzymatically catalyzed drug release, and the highest cytotoxicity in vitro.

References provided by Crossref.org

Newest 20 citations...

See more in
Medvik | PubMed

Polymer-Antimicrobial Peptide Constructs with Tailored Drug-Release Behavior

. 2023 Jan 25 ; 15 (2) : . [epub] 20230125

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...